uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here....

Seeking Alpha - 5/8/2025 5:16:15 AM More News for PTC
Stock Analysis for PTC
Related Stocks: